1.Sei, S., et al., Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer, 2009. 8(1): p. 47.
2.Min, H.-J., et al., Inhibition of GSK–3β enhances reovirus-induced apoptosis in colon cancer cells. Int J Oncol, 2009. 35(3): p. 617–624.
3.Shmulevitz, M., P. Marcato, and P. W. Lee, Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene, 2005. 24(52): p. 7720.
4.Thirukkumaran, C., et al., PUMA and NF-kB are cell signaling predictors of reovirus oncolysis of breast cancer. PloS one, 2017. 12(1): p. e0168233.
5.Kemp, V., R. Hoeben, and D. van den Wollenberg, Exploring reovirus plasticity for improving its use as oncolytic virus. Viruses, 2016. 8(1): p. 4.
6.Phillips, M. B., et al., Current understanding of reovirus oncolysis mechanisms. Oncolytic Virother, 2018. 7: p. 53.
7.Coffey, M. C., et al., Reovirus therapy of tumors with activated Ras pathway. Science, 1998. 282(5392): p. 1332–1334.
8.Marcato, P., M. Shmulevitz, and P. W. Lee, Connecting reovirus oncolysis and Ras signaling. Cell cycle, 2005. 4(4): p. 556–556.
9.Shmulevitz, M., P. Marcato, and P. Lee, Activated Ras signaling significantly enhances reovirus replication and spread. Cancer Gene Ther, 2010. 17(1): p. 69.
10.Karoulia, Z., E. Gavathiotis, and P. I. Poulikakos, New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer, 2017. 17(11): p. 676.
11.Logsdon, C. D. and W. Lu, The significance of Ras activity in pancreatic cancer initiation. Int J Biol Sci, 2016. 12(3): p. 338.
12.Jin, H., et al., Restoration of mutant K-Ras repressed miR–199b inhibits K-Ras mutant non-small cell lung cancer progression. J Exp Clin Cancer Res, 2019. 38(1): p. 165.
13.Mostafa, A., et al., Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. Cancers, 2018. 10(6): p. 205.
14.van de Merbel, A. F., et al., Oncolytic reovirus variants induce direct oncolysis in human prostate cancer. 2019, AACR.
15.Drerup, J. M., et al., Immunotherapy for ovarian cancer. Curr Treat Options Oncol, 2015. 16(1): p. 1.
16.Siegel, R. L., et al., Colorectal cancer statistics, 2017. CA Cancer J Clin, 2017. 67(3): p. 177–193.
17.Garofalo, M., et al., Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release, 2018. 283: p. 223–234.
18.Kaufman, H. L., F. J. Kohlhapp, and A. Zloza, Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov, 2015. 14(9): p. 642–662.
19.Chakrabarty, R., et al., The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest New Drugs, 2015. 33(3): p. 761–774.
20.Kemp, V., R. C. Hoeben, and D. J. van den Wollenberg, Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. Viruses, 2015. 8(1): p. 4.
21.Poggioli, G. J., et al., Reovirus-induced G2/M cell cycle arrest requires ς1s and occurs in the absence of apoptosis. J Virol, 2000. 74(20): p. 9562–9570.
22.Twigger, K., et al., Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res, 2008. 14(3): p. 912–923.
23.Chulu, J. L., et al., Apoptosis induction by avian reovirus through p53 and mitochondria-mediated pathway. Biochem Biophys Res Commun, 2007. 356(3): p. 529–535.
24.Bardelli, A., et al., Kras mutations and resistance to anti-egfr treatment. 2016, Google Patents.
25.Qu, X., et al., Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene, 2016. 35(50): p. 6403.
26.Liang, K.-H., et al., Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett, 2018. 433: p. 165–175.
27.Norman, K. L., et al., Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A, 2004. 101(30): p. 11099–11104.
28.Hashiro, G., P. Loh, and J. T. Yau, The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol, 1977. 54(4): p. 307–315.
29.Hirasawa, K., et al., Oncolytic reovirus against ovarian and colon cancer. Cancer Res, 2002. 62(6): p. 1696–1701.
30.Norman, K. L. and P. W. Lee, Reovirus as a novel oncolytic agent. J Clin Invest, 2000. 105(8): p. 1035–1038.
31.Beckham, J. D., K. D. Tuttle, and K. L. Tyler, Caspase–3 activation is required for reovirus-induced encephalitis in vivo. J Neurovirol, 2010. 16(4): p. 306–317.
32.Berger, A. K. and P. Danthi, Reovirus activates a caspase-independent cell death pathway. MBio, 2013. 4(3): p. e00178–13.
33.Kominsky, D., R. Bickel, and K. Tyler, Reovirus-induced apoptosis requires both death receptor-and mitochondrial-mediated caspase-dependent pathways of cell death. Cell Death Differ, 2002. 9(9): p. 926.
34.Clarke, P., et al., Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene, 2001. 20(47): p. 6910.
35.Kemp, V., R. C. Hoeben, and D. J. Van den Wollenberg, Exploring reovirus plasticity for improving its use as oncolytic virus. Viruses, 2016. 8(1): p. 4.
36.Hiller, B. E., A. K. Berger, and P. Danthi, Viral gene expression potentiates reovirus-induced necrosis. Virology, 2015. 484: p. 386–394.
37.Tyler, K. L., et al., Linkage between reovirus-induced apoptosis and inhibition of cellular DNA synthesis: role of the S1 and M2 genes. J Virol, 1996. 70(11): p. 7984–7991.
38.Zhang, B., et al., Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Cancer Lett, 2009. 277(1): p. 114–120.
39.Tyler, K. L., et al., Reoviruses and the host cell. Trends Microbiol, 2001. 9(11): p. 560–564.
40.Kim, M., et al., Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene, 2007. 26(28): p. 4124.
41.Smith, R. E., H. Zweerink, and W. K. Joklik, Polypeptide components of virions, top component and cores of reovirus type 3. Virology, 1969. 39(4): p. 791–810.
42.Razieh Sadat Banijamali, et al., Kinetics Of Oncolytic Reovirus T3D Replication And Growth Pattern In Mesenchymal Stem Cells. cell J, 2020. 22(Volume 22, Number 3, Autumn 2020, Serial Number: 87).
43.Maitra, R., et al., Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget, 2014. 5(9): p. 2807.
44.Crowley, L. C., et al., Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc, 2016. 2016(11): p. pdb. prot087288.
45.Kalejta, R. F., T. Shenk, and A. J. Beavis, Use of a membrane‐localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. Cytometry, 1997. 29(4): p. 286–291.